Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous Oritavancin for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

NCT05599295 is registered in ClinicalTrials.gov with Melinta Therapeutics, LLC as lead sponsor.

NCT NCT05599295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05599295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous Oritavancin for the Treatment of Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections
Lead sponsor
Melinta Therapeutics, LLC
Phase
Phase 2
Overall status
Completed
Start date
June 15, 2023
Completion date
November 20, 2025
Enrollment
118 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

acute bacterial skin and skin structure infection